Please login to the form below
Zinbryta
This page shows the latest Zinbryta news and features for those working in and with pharma, biotech and healthcare.
Biogen and AbbVie pull MS drug Zinbryta from the market
Biogen and AbbVie have voluntarily withdrawn their multiple sclerosis drug Zinbryta from the market worldwide, saying the move is in the best interests of patients. ... The EMA recommends that doctors should review patients currently treated with
Latest news
-
Roche sets disruptive price for new MS drug Ocrevus in US
remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).
-
NICE backtracks on Biogen's multiple sclerosis drug Zinbryta
NICE turned down Zinbryta in draft guidance issued last October, criticising the analysis submitted by Biogen of the cost effectiveness of daclizumab compared with other disease-modifying treatments. ... Zinbryta is also being considered for use by the
-
Biogen elevates Vounatsos to top seat
recently-approved Zinbryta (daclizumab) and bringing forward phase III Alzheimer's disease candidate aducanumab.
-
Biogen's CEO Scangos to step down
Vounatsos highlighted the prospects for just-approved Zinbryta (daclizumab), a once-monthly MS therapy which is due for launch in the US and Germany next month, as well as the
-
Roche's MS drug Ocrevus awarded priority review by FDA
If approved Ocrevus will compete for MS market share with Biogen's recently-approved Zinbryta, while Novartis has an anti-B cell candidate in its pipeline, which the company claims has
More from news
Approximately 6 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
Windrose Consulting Group
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
